Read by QxMD icon Read

Transarterial Chemoembolization

Haruki Kimura, Kazuyoshi Ohkawa, Masanori Miyazaki, Mitsuru Sakakibara, Kazuho Imanaka, Takeshi Tamura, Hironari Sueyoshi, Ryoji Takada, Nobuyasu Fukutake, Hiroyuki Uehara, Reiko Ashida, Tatsuya Ioka, Tetsuro Nakazawa, Katsuyuki Nakanishi, Kazuhiro Katayama
BACKGROUND: Intermediate-stage [Barcelona Clinic Liver Cancer stage-B (BCLC-B)] hepatocellular carcinoma (HCC) comprises of a heterogeneous population of patients with a wide range of tumor burdens. We therefore formulated a subclassification of BCLC-B HCC using the up-to-seven criteria and tumor markers according to the results of a retrospective analysis of these patients. METHODS: This study included 125 patients newly diagnosed with BCLC-B HCC who underwent transarterial chemoembolization...
October 20, 2016: Hepatology International
K B Huang, W Z Fan, Y Y Zhang, Y Wang, W Cui, J P Li
Objective: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with cryoablation in patients with unresectable large hepatocellular carcinoma (HCC). Methods: A total of 122 patients with unresectable large HCC admitted to the First Affiliated Hospital of Sun Yat-sen University between November 2011 and July 2015 were retrospectively involved.The patients were divided into study group (58 patients who underwent TACE combined with cryoablation) and control group (64 patients who underwent TACE alone)...
October 11, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Lívia C Lionço, Angelo A de Mattos, Alex F Horbe, Ane M Costabeber, Ângelo Z de Mattos, Dorvaldo P Tarasconi
OBJECTIVE: The main aim of this study was to evaluate the real-life survival rates of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. METHODS: A retrospective cohort study involving 95 patients was conducted and the studied variables were analysed according to survival. Treatment response was determined using the Modified Response Evaluation Criteria in Solid Tumors assessment. The Kaplan-Meier method and Cox regression were used to analyse survival...
October 18, 2016: European Journal of Gastroenterology & Hepatology
Tadaaki Arizumi, Kazuomi Ueshima, Mina Iwanishi, Tomohiro Minami, Hirokazu Chishina, Masashi Kono, Masahiro Takita, Satoshi Kitai, Tatsuo Inoue, Norihisa Yada, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Toshiharu Sakurai, Masayuki Kitano, Naoshi Nishida, Masatoshi Kudo
BACKGROUND: The standard treatment option that is available for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE). However, the condition of the patients with BCLC stage B disease is heterogeneous showing different tumor statuses and Child-Pugh scores; treatment strategies other than TACE are frequently employed for the patients in this stage. Based on the subclassification system proposed by Bolondi et al...
2016: Digestive Diseases
James X Chen, Steven Rose, Sarah B White, Ghassan El-Haddad, Nicholas Fidelman, Hooman Yarmohammadi, Winifred Hwang, Daniel Y Sze, Nishita Kothary, Kristen Stashek, E Paul Wileyto, Riad Salem, David C Metz, Michael C Soulen
PURPOSE: The purpose of the study was to evaluate prognostic factors for survival outcomes following embolotherapy for neuroendocrine tumor (NET) liver metastases. MATERIALS AND METHODS: This was a multicenter retrospective study of 155 patients (60 years mean age, 57 % male) with NET liver metastases from pancreas (n = 71), gut (n = 68), lung (n = 8), or other/unknown (n = 8) primary sites treated with conventional transarterial chemoembolization (TACE, n = 50), transarterial radioembolization (TARE, n = 64), or transarterial embolization (TAE, n = 41) between 2004 and 2015...
October 13, 2016: Cardiovascular and Interventional Radiology
F Y Wang, W Meng, Y Li, T Li, C Y Qin
Transarterial chemoembolization (TACE) has mostly been used in hypervascular tumours such as hepatocellular carcinoma, and may be an effective palliative treatment in patients with metastatic liver cancer. Our goal is to determine whether TACE increases overall survival (OS) of in patients with liver metastases. The retrospective cohort study included 171 patients with liver metastases diagnosed between 2001 and 2015. OS was compared between the TACE and non-TACE groups after propensity score matching to reduce the effects of selection bias and potential confounders...
October 13, 2016: Scientific Reports
Alvin Ho-Kwan Cheung, Colin Siu-Chi Lam, Henry Shiu-Cheung Tam, Tan-To Cheung, Roberta Pang, Ronnie Tung-Ping Poon
BACKGROUND: Chemoembolization with doxorubucin-eluting beads (DEB) has been used to treat hepatocellular carcinoma (HCC) since 2007. This study compared the efficacy and survival between transarterial chemoembolization (TACE) with DEB and conventional approach (cTACE) in HCC treatment. METHODS: This retrospective case-control study compared the overall survival and tumor response of HCC patients to cTACE (n=190) and DEB (n=143) by the reassessment of computed tomography and serum alpha-fetoprotein (AFP)...
October 2016: Hepatobiliary & Pancreatic Diseases International: HBPD INT
Jing-Huan Li, Yan Wang, Xiao-Ying Xie, Xin Yin, Lan Zhang, Rong-Xin Chen, Zheng-Gang Ren
Transarterial chemoembolization (TACE) is the principal therapy for unresectable hepatocellular carcinoma (HCC). However, its efficacy is currently limited owing to tumor progression or treatment failure. It has been shown that aspirin reduces the incidence of multiple malignant tumors including HCC and plays a synergistic role with chemotherapy in the treatment of colon cancer. Therefore, we aimed to investigate the adjuvant effect of aspirin on patients with unresectable HCC who underwent TACE therapy. A retrospective matched-pairs analysis was performed to evaluate the efficacy of aspirin in combination with TACE therapy...
2016: American Journal of Cancer Research
Jungang Hu, Majid Maybody, Guang Cao, Xiao Wang, Hui Chen, Xu Zhu, Renjie Yang, Xiaodong Wang
BACKGROUND: To investigate accuracy of intraprocedural cone beam computed tomography (CBCT) compared to fluoroscopy for detection of lipiodol retention pattern during conventional transarterial chemoembolization (cTACE) of hepatocellular carcinoma (HCC) and its correlation with short-term response. METHODS: Between September 2013 and July 2014, 29 patients with HCC underwent chemoembolization of 51 tumors (mean diameter 28.1 mm, range 10.0-136.3 mm). Lipiodol retention pattern was assessed by CBCT at the endpoint of cTACE compared by fluoroscopy...
October 3, 2016: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
Yan Zhao, Rafael Duran, Julius Chapiro, Jae Ho Sohn, Sonia Sahu, Florian Fleckenstein, Susanne Smolka, Timothy M Pawlik, Rüdiger Schernthaner, Li Zhao, Howard Lee, Shuixiang He, MingDe Lin, Jean-François Geschwind
It remains controversial whether transarterial chemoembolization (TACE) should be performed in patients with advanced-stage hepatocellular carcinoma (HCC). The present large retrospective cohort study aimed to define the survival outcome following TACE of advanced HCC and to identify the prognostic factors. Five hundred eight patients with Barcelona Clinic Liver Cancer (BCLC) C-stage HCC, Child-Pugh A/B who were treated with TACE between November 1998 and December 2013 were identified. There was no significant difference in overall survival (OS) between patients with Eastern Cooperative Oncology Group (ECOG) 0 and those with ECOG ≥1 (10...
October 6, 2016: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
Wei-Hsiang Lin, Shiou-Hwei Yeh, Kun-Huei Yeh, Kai-Wei Chen, Ya-Wen Cheng, Tung-Hung Su, Ping Jao, Lin-Chun Ni, Pei-Jer Chen, Ding-Shinn Chen
Transarterial chemoembolization (TACE) is the main treatment for intermediate stage hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer classification because of its exclusive arterial blood supply. Although TACE achieves substantial necrosis of the tumor, complete tumor necrosis is uncommon, and the residual tumor generally rapidly recurs. We combined tirapazamine (TPZ), a hypoxia-activated cytotoxic agent, with hepatic artery ligation (HAL), which recapitulates transarterial embolization in mouse models, to enhance the efficacy of TACE...
October 4, 2016: Proceedings of the National Academy of Sciences of the United States of America
S B Paul, E Dhamija, S R Gamanagatti, V Sreenivas, D P Yadav, S Jain, Shalimar, S K Acharya
PURPOSE: To compare the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) with that of multiphase computed tomography (CT) in the evaluation of tumor response to transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). MATERIAL AND METHODS: Fifty patients (41 men, 9 women; mean age, 53 years±12.5 [SD]) with a total of 70 HCCs (mean size, 5cm±3 [SD]) were evaluated. Post-TACE therapeutic assessment of HCC was done at 4 weeks. Patients with TACE done earlier and reporting with suspicion for recurrence were also included...
September 27, 2016: Diagnostic and Interventional Imaging
Jian-Ping Dou, Jie Yu, Zhi-Yu Han, Fang-Yi Liu, Zhi-Gang Cheng, Ping Liang
PURPOSE: To evaluate the feasibility, efficacy, and safety of microwave ablation (MWA) in the treatment of hepatocellular carcinoma associated with Budd-Chiari syndrome (BCS) after transarterial chemoembolization (TACE). METHODS: A total of 10 patients (mean 50.0 ± 7.5 years) with 15 BCS-associated HCC lesions were retrospectively evaluated. All patients received MWA treatment for residual tumors after 1 to 3 sessions of TACE. The diagnosis of residual tumors was confirmed by at least two types of enhanced imaging...
September 29, 2016: Abdominal Radiology
Wenjun Wang, Wei Bai, Enxin Wang, Yan Zhao, Lei Liu, Man Yang, Hongwei Cai, Dongdong Xia, Lei Zhang, Jing Niu, Zhanxin Yin, Zhuoli Zhang, Daiming Fan, Jielai Xia, Guohong Han
The mRECIST and dermatologic adverse events (AEs) can be used to assess the patient response to transarterial chemoembolization (TACE) and/or sorafenib for hepatocellular carcinoma (HCC). Here, we aimed to combine the two criteria to stratify the prognosis in patients with unresectable HCC receiving TACE plus sorafenib (TACE-S). In total, 176 consecutive HCC patients treated with TACE-S were enrolled. CT scans and laboratory tests were conducted pretreatment (at baseline, 5-7 days before the TACE-S) and post-treatment (at 1, 2 and 3 months)...
September 28, 2016: International Journal of Cancer. Journal International du Cancer
L Dover, D DuBay, P Li, D Redden, S Saddekni, S Shen, R Jacob
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
E Sapir, W C Jackson, L Bazzi, P Novelli, P Neehar, T S Lawrence, M Feng
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
C L Chiang, A S Lee, K K Choi, S Y Yeung, Y P Wong, W K Leung, W Y Lee, M Chan, S Y Tung
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Y Zhao, W H Wang, Y X Li
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Mashaal Dhir, Ruchi Shrestha, Jennifer L Steel, J Wallis Marsh, Allan Tsung, Mitchel E Tublin, Nikhil B Amesur, Philip D Orons, Ernesto Santos, David A Geller
BACKGROUND: The majority of patients with neuroendocrine tumor liver metastases (NELM) present with multifocal disease and are not surgical candidates. We present our 20-year experience with transarterial chemoembolization (TACE) using streptozotocin (STZ) in patients with initially unresectable NELM. METHODS: Patients with unresectable NELM treated with TACE using STZ at a single institution from 1995 to 2015 were identified after institutional board approval. Imaging was independently reviewed by a radiologist to evaluate for RECIST 1...
September 23, 2016: Annals of Surgical Oncology
F Abdul Rahman, J Naidu, C S Ngiu, Y Yaakob, Z Mohamed, H Othman, R Jarmin, M H Elias, N Abdul Hamid, N Mohd Mokhtar, Ra Raja Ali
BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer that is frequently diagnosed at an advanced stage. Transarterial chemoembolisation (TACE) is an effective palliative treatment for patients who are not eligible for curative treatment. The two main methods for performing TACE are conventional (c-TACE) or with drug eluting beads (DEB-TACE). We sought to compare survival rates and tumour response between patients undergoing c-TACE and DEB-TACE at our centre. MATERIALS AND METHODS: A retrospective cohort study of patients undergoing either treatment was carried out from January 2009 to December 2014...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"